Edelfosine (Synonyms: ET-18-OCH3)

Cat. No.: HY-108610A Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Edelfosine (ET-18-OCH3) is a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 Death receptor.

For research use only. We do not sell to patients.

Edelfosine Chemical Structure

CAS No. : 70641-51-9

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Edelfosine:

(R)-Edelfosine Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Edelfosine (ET-18-OCH3) is a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 Death receptor^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	3.5 μM Compound: 3, ET-18-OMe	Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA Inhibition of Akt phosphorylation in human insulin-stimulated A549 cells incubated for 2 hrs prior to insulin-induction measured after 30 mins by ELISA	[PMID: 23415083]
A549	IC₅₀	7.4 μM Compound: 3, ET-18-OMe	Cytotoxicity against human A549 cells by flow cytometric analysis Cytotoxicity against human A549 cells by flow cytometric analysis	[PMID: 23415083]
BXPC-3	IC₅₀	18.8 μM Compound: EDLF	Growth inhibition of human BxPC3 cells after 72 hrs by XTT assay Growth inhibition of human BxPC3 cells after 72 hrs by XTT assay	[PMID: 29547833]
CEM-SS	IC₅₀	4 μM Compound: ET-18-OMe	In vitro inhibition of CEM-SS cell growth by 50 % In vitro inhibition of CEM-SS cell growth by 50 %	[PMID: 2016713]
HL-60	IC₅₀	6.1 μM Compound: Edelfosine	Cytotoxicity measured in HL-60 leukemic cells after a 24 hr incubation period. Cytotoxicity measured in HL-60 leukemic cells after a 24 hr incubation period.	[PMID: 7707324]
Jurkat	IC₅₀	12.2 μM Compound: Edelfosine	Cytotoxicity against human Jurkat cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay Cytotoxicity against human Jurkat cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay	[PMID: 21571403]
MCF7	IC₅₀	9.3 μM Compound: 3, ET-18-OMe	Cytotoxicity against human MCF7 cells by flow cytometric analysis Cytotoxicity against human MCF7 cells by flow cytometric analysis	[PMID: 23415083]
MDA-MB-435	IC₅₀	12 μM Compound: ET-18-OCH3	Cytotoxicity against human MDA-MB-435 cells after 3 days in serum free conditions by MTT assay Cytotoxicity against human MDA-MB-435 cells after 3 days in serum free conditions by MTT assay	[PMID: 16279790]
MDA-MB-435	IC₅₀	3 μM Compound: ET-18-OCH3	Inhibition of Akt phosphorylation in MDA-MB-435 cells after 2 hrs Inhibition of Akt phosphorylation in MDA-MB-435 cells after 2 hrs	[PMID: 16279790]
PANC-1	IC₅₀	25.7 μM Compound: EDLF	Growth inhibition of human PANC1 cells after 72 hrs by XTT assay Growth inhibition of human PANC1 cells after 72 hrs by XTT assay	[PMID: 29547833]
THP-1	EC₅₀	1 μM Compound: Edelfosine	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by propidium iodide staining based fluorescence microscopic analysis Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by propidium iodide staining based fluorescence microscopic analysis	[PMID: 29501944]
THP-1	IC₅₀	3.1 μM Compound: Edelfosine	Leishmanicidal activity against amastigote stage of Leishmania infantum expressing GFP infected in human THP1 cells after 48 hrs by flow cytometric analysis Leishmanicidal activity against amastigote stage of Leishmania infantum expressing GFP infected in human THP1 cells after 48 hrs by flow cytometric analysis	[PMID: 24448421]
THP-1	IC₅₀	4.9 μM Compound: Edelfosine	Cytotoxicity against human THP1 cells after 24 hrs by propidium iodide staining-based flow cytometric analysis Cytotoxicity against human THP1 cells after 24 hrs by propidium iodide staining-based flow cytometric analysis	[PMID: 24448421]
THP-1	IC₅₀	4.96 μM Compound: Edelfosine	Cytotoxicity against human THP1 cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay Cytotoxicity against human THP1 cells assessed as live cells in neubauer chamber after 24 hrs by trypan blue assay	[PMID: 21571403]
THP-1	IC₅₀	4.96 μM Compound: Edelfosine	Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 24 hrs Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 24 hrs	[PMID: 32738977]
THP-1	IC₅₀	4.96 μM Compound: Edelfosine	Cytotoxicity against human THP1 cells assessed as reduction in cell viability measured after 24 hrs by propidium iodide staining based flow cytometry Cytotoxicity against human THP1 cells assessed as reduction in cell viability measured after 24 hrs by propidium iodide staining based flow cytometry	[PMID: 32223141]

Molecular Weight

523.73

Formula

C₂₇H₅₈NO₆P

CAS No.

70641-51-9

Appearance

Solid

Color

Colorless to off-white

SMILES

CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(OCC[N+](C)(C)C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (47.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9094 mL	9.5469 mL	19.0938 mL
5 mM	0.3819 mL	1.9094 mL	3.8188 mL
10 mM	0.1909 mL	0.9547 mL	1.9094 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.39 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.39 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (2.39 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 25 mg/mL (47.73 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (265 KB) SDS (251 KB)

COA (239 KB)

Handling Instructions (2659 KB)

References

[1]. Mollinedo F, et al. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem. 2004;11(24):3163-3184. doi:10.2174/0929867043363703 IF: 4.1 Q2 B4 [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9094 mL	9.5469 mL	19.0938 mL	47.7345 mL
	5 mM	0.3819 mL	1.9094 mL	3.8188 mL	9.5469 mL
	10 mM	0.1909 mL	0.9547 mL	1.9094 mL	4.7735 mL
	15 mM	0.1273 mL	0.6365 mL	1.2729 mL	3.1823 mL
	20 mM	0.0955 mL	0.4773 mL	0.9547 mL	2.3867 mL
	25 mM	0.0764 mL	0.3819 mL	0.7638 mL	1.9094 mL
	30 mM	0.0636 mL	0.3182 mL	0.6365 mL	1.5912 mL
	40 mM	0.0477 mL	0.2387 mL	0.4773 mL	1.1934 mL

Edelfosine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Edelfosine70641-51-9ET-18-OCH3Apoptosisantitumour ether lipidapoptosissignal transductionFas/CD95molecular modellingcancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks